Trial · NCT06232044
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
NCT06232044, Phase 1, Phase 2, Suspended, Alliance for Clinical Trials in Oncology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma. Trials, record NCT06232044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06232044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
- NCT number
- NCT06232044
- Status
- Suspended
- Phases
- Phase 1, Phase 2
- Enrollment
- 88 participants, estimated
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- First posted
- 2024-01-30
- Last updated
- 2026-10-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose (MTD) of iberdomide (Phase I) | During the first cycle of therapy, up to 28 days | MTD will be defined as the highest dose level among those tested where at most one out of 6 patients develops a DLT prior to the start of their second cycle of treatment. Will be assessed by NCI CTCAE v 5.0. |
| Primary | Progression-free survival (PFS) (Phase II) | From randomization to the time of documented disease progression and/or death due to any cause, assessed up to 3 years | Will be compared between the two treatment arms. the methods of Kaplan and Meier will be used to graphically evaluate these distributions as well as to estimate the median PFS and corresponding 95% confidence intervals. |
| Secondary | Rate of grade 3+ Adverse Events (AEs) | Up to 3 years | Will be collected and graded according to the NCI CTCAE v 5.0 criteria. |
| Secondary | Complete response (CR) rate | up to 3 years | Will be estimated for each treatment arm and calculated as the number of patients with CR divided by the total number of patients randomized. For each treatment arm, CR rates will be estimated with their 95% confidence intervals. |
| Secondary | Overall response rate (ORR) | up to 3 years | : Overall response includes complete, very good partial, and partial responses. ORR will be estimated for each treatment arm and calculated as the number of patients with response divided by the total number of patients randomized. For each treatment arm, ORRs will be estimated with their 95% confidence intervals. |
| Secondary | Duration of response (DoR) | p to 3 years | : DoR will be calculated for patients with a complete, very good partial, or partial response from the first date of response until the earlier of disease progression, death from any cause, or non-protocol myeloma-directed therapy to treat residual or progressive disease. Patients alive and progression-free at the date of last known clinical assessment or at the last assessment date prior to beginning a non-protocol myeloma-directed therapy for reasons other than residual or progressive disease will be censored. The Kaplan-Meier method will be used to estimate duration of response for each treatment arm. |
| Secondary | Overall Survival (OS) | Up to 3 years. | OS will be calculated from randomization date until death from any cause, censoring patients alive at the date of last contact. The Kaplan-Meier method will be used to estimate OS for each treatment arm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06232044
GET https://conductscience.org/api/trials/v1/NCT06232044/registered